Analyst
Jefferies
Equibles does not estimate personal net worth.
Akash Tewari is recorded as Analyst at Jefferies. Akash Tewari has spoken on 5 earnings calls across 4 companies, most recently for Merck & Co., Inc. on August 4, 2026. Those appearances were for Bristol Myers Squibb Co (BMY), Merck & Co., Inc. (MRK), ELI LILLY & Co (LLY) and Regeneron Pharmaceuticals, Inc. (REGN). The companies whose calls Akash Tewari spoke on are classified in the Healthcare sector.
“Dean, you've simply stated a biomarker strategy would be the right approach for a first line and a CLC.”
“So for your CABENFI Alzheimer's psychosis studies, you have several trials, but I know ADEPT-4 requires patients to have a confirmed Alzheimer's diagnosis using both imaging and blood-based biomarkers.”
“So Dave, you've mentioned that investors are really understand, really recognize it's a consumer stock. Can you talk about some consumer analogs you'd point investors towards when you're thinking about long-term penetration for both the US and ex-US for your weight loss product?”
“On your PCS-Gen9-GitGlip combo, can you talk about the co-formulation here? How are you able to deliver both drugs in a single auto-injector versus something akin to an on-body infusion?”
“So what's the risk around the adjunct schizophrenia trial for Cobenfy? Because we haven't seen a lot of companies run that specific trial. And if they have, they've often failed.”
Jefferies
Analyst
Source not stated
Drug Manufacturers - General · Healthcare
Drug Manufacturers - General · Healthcare
LLY
Drug Manufacturers - General · Healthcare
